Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nat Res Council CanadafiledCriticalNat Res Council Canada
Publication of BR112022006595A2publicationCriticalpatent/BR112022006595A2/en
Micro-Organisms Or Cultivation Processes Thereof
(AREA)
Preparation Of Compounds By Using Micro-Organisms
(AREA)
Abstract
ORIGEM VIRAL DE REPLICAÇÃO PARA AUMENTAR A PRODUTIVIDADE DE PROTEÍNAS DE CÉLULAS DE MAMÍFEROS. A presente divulgação refere-se ao uso de uma origem de replicação do vírus Epstein Barr (oriP) ou um fragmento funcional do mesmo em um construção de expressão de proteína para aumentar a produção de uma proteína de interesse em células de mamífero. Também são divulgadas construções de expressão de proteína para produção aumentada de anticorpos em células de mamífero e células de mamífero contendo as construções de expressão.VIRAL ORIGIN OF REPLICATION TO INCREASE THE PRODUCTIVITY OF MAMMALIAN CELL PROTEINS. The present disclosure relates to the use of an Epstein Barr virus origin of replication (oriP) or a functional fragment thereof in a protein expression construct to enhance production of a protein of interest in mammalian cells. Also disclosed are protein expression constructs for increased production of antibodies in mammalian cells and mammalian cells containing the expression constructs.
BR112022006595A2019-10-302020-10-27
VIRAL ORIGIN OF REPLICATION TO INCREASE THE PRODUCTIVITY OF MAMMALIAN CELL PROTEINS.
BR112022006595A2
(en)
scalable methods for producing recombinant adeno-associated viral vector (aav) in a serum-free suspension cell culture system suitable for clinical use
polypeptide, a composition comprising said polypeptide, protein complex, nucleotide sequence, cell expression vector, and methods for preparing the protein complex, for preparing a fviii, and for enhancing a plasma pharmacokinetic property of a fviii
METHODS TO PRODUCE THE VESICULAR STOMATITIS VIRUS (VSV) ATTACHED IN A CELL CULTURE AND TO IMPROVE THE VSV PACK OF DEFECTIVE PROPAGATION, IMMUNOGENIC COMPOSITION, ISOLATED CELL AND TRANSCRIPTIONAL CONTROL SEQUENCE
MULTI-SPECIFIC PROTEIN, PHARMACEUTICAL COMPOSITION, RECOMBINANT CELL, METHOD OF PREPARING AN NK CELL COMPOSITION, NK CELL COMPOSITION, USE OF A PROTEIN OR COMPOSITION, METHODS AND USE